Respiratory Syncytial Virus–Related Pediatric Intensive Care Unit Admissions in Children During Their Second RSV Season

Importance Respiratory syncytial virus (RSV) hospitalization rates are highest among children younger than 2 years. For certain high-risk children entering their second RSV season, the monoclonal antibody nirsevimab is recommended. Little is known regarding preexisting health conditions as risk factors for RSV-related respiratory failure in children during their second RSV season. Objective To describe children admitted to the pediatric intensive care unit (PICU) for severe RSV by classifying them by their nirsevimab eligibility status and preexisting health conditions, and comparing their demographic and clinical characteristics. Design, Setting, and Participants This cohort study analyzed US children aged 8 to 23 months admitted to the PICU in 30 pediatric hospitals in the 2023 to 2024 and 2024 to 2025 RSV seasons. All children had an RSV-positive result from a respiratory sample and received respiratory support with high-flow nasal cannula, noninvasive ventilation, or invasive mechanical ventilation. Analyses were based on the US criteria for second-season nirsevimab eligibility as recommended in August 2023. Exposure Preexisting health conditions potentially associated with increased risk of severe RSV disease. Patients were classified into 4 mutually exclusive groups of eligibility status and preexisting health conditions: (1) met nirsevimab eligibility criteria, (2) with other identified RSV risk conditions (with some evidence of increased risk for severe RSV), (3) with other preexisting conditions, and (4) with no preexisting conditions. Main Outcomes and Measures Patient demographic characteristics and level of respiratory support received were compared by level of preexisting health conditions. Results A total of 574 children (median [IQR] age, 1.2 [1.1-1.5] years; 317 males [55.2%]) were included. Overall, 47 patients (8.2%) met the nirsevimab eligibility criteria, 76 (13.2%) had other identified RSV risk conditions, 96 (16.7%) had other preexisting conditions, and 355 (61.8%) had no preexisting conditions. A higher proportion of children who met nirsevimab eligibility criteria required invasive mechanical ventilation vs children with other identified RSV risk conditions, those with other preexisting health conditions, or those with no preexisting health conditions (40.4% [19 of 47] vs 17.1% [13 of 76], 10.4% [10 of 96], 5.9% [21 of 355]; P for trend <.001). Conclusions and Relevance Among children admitted to the PICU for severe RSV, 8.2% met the nirsevimab eligibility criteria and 13.2% had other identified RSV risk conditions. These findings might help inform future deliberations regarding second RSV season recommendations for nirsevimab eligibility in the US.

Authors

Institutions

Publication Details

Journal
JAMA Network Open
Published
2026-11-19
DOI
https://doi.org/10.1001/jamanetworkopen.2026.41333
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Respiratory Syncytial Virus–Related Pediatric Intensive Care Unit Admissions in Children During Their Second RSV Season

Satoshi Kamidani, Jennifer E. Schuster, Allison Scott, Natasha Baig et al.
5 links
JAMA Network Open
Respiratory viral infections research
article

Respiratory Syncytial Virus–Related Pediatric Intensive Care Unit Admissions in Children During Their Second RSV Season

Satoshi Kamidani, Jennifer E. Schuster, Allison Scott, Natasha Baig, Janet R. Hume, Emily Ruth Levy, Caroline Rose Ciric, Heather Kelley, Mary Stumpf, Margaret M. Newhams, Masson Yates, Kari Wellnitz, Bria M. Coates, Tamara T. Bradford, Danielle M. Zerr, Katherine Irby, Ariana F. Valenzuela, Austin Biggs, Ryan A. Nofziger, Mary K. Prahl, Regina M. Simeone, Meghan Murdock, Natasha Halasa, Kathleen Chiotos, Stockwell Ml, Lora Martin, Hillary Crandall, Samina S. Bhumbra, Aline B. Maddux, Melissa A. Cameron, Scott L. Weiss, Mia Maamari, Mary Allen Staat, Rebecca Clifford, Katherine N. Lindsey, Joanna Ly, Laura Divens Zambrano, Stephanie P. Schwartz, Shira J. Gertz, Matt S. Zinter, Emily R. Levy, Adrienne G. Randolph, Judith A. Guzman‐Cottrill, Jigar Chauhan, Rachel Greer, Jamie Laurin, Luis W Salazar, Michele Y. F. Kong, Amanda B. Payne, Steven L. Shein, Candice Colston, Lacy Malloch, Angela P. Campbell, Kelly Nicole Michelson, Lexi Petruccelli, Amber O. Orzel-Lockwood, Ashlyn Madding, Sara Shankman, Heidi Sauceda, Jemima M. Calixte, Jong-Ha C. Choi, Maygan Martin, Ronald C. Sanders, Mark D. Gonzalez, Gabriella Ess, Jenna Lapira, Janelle J. Spencer-Ramirez, Berenice Marrufo, Chloe A Schluttner, Saul Hymes, Anna K Mitchell, Amira Toivonen, L Dailey, Michael Henne, Lora M. Martine, Katrina Saladin, Carly R. Crowley, Overcoming RSV Investigators, Callum Ackerman, Judy Kyrkos, Joesph M. Majure, Sara Jae Wershil
article en

Abstract

Importance Respiratory syncytial virus (RSV) hospitalization rates are highest among children younger than 2 years. For certain high-risk children entering their second RSV season, the monoclonal antibody nirsevimab is recommended. Little is known regarding preexisting health conditions as risk factors for RSV-related respiratory failure in children during their second RSV season. Objective To describe children admitted to the pediatric intensive care unit (PICU) for severe RSV by classifying them by their nirsevimab eligibility status and preexisting health conditions, and comparing their demographic and clinical characteristics. Design, Setting, and Participants This cohort study analyzed US children aged 8 to 23 months admitted to the PICU in 30 pediatric hospitals in the 2023 to 2024 and 2024 to 2025 RSV seasons. All children had an RSV-positive result from a respiratory sample and received respiratory support with high-flow nasal cannula, noninvasive ventilation, or invasive mechanical ventilation. Analyses were based on the US criteria for second-season nirsevimab eligibility as recommended in August 2023. Exposure Preexisting health conditions potentially associated with increased risk of severe RSV disease. Patients were classified into 4 mutually exclusive groups of eligibility status and preexisting health conditions: (1) met nirsevimab eligibility criteria, (2) with other identified RSV risk conditions (with some evidence of increased risk for severe RSV), (3) with other preexisting conditions, and (4) with no preexisting conditions. Main Outcomes and Measures Patient demographic characteristics and level of respiratory support received were compared by level of preexisting health conditions. Results A total of 574 children (median [IQR] age, 1.2 [1.1-1.5] years; 317 males [55.2%]) were included. Overall, 47 patients (8.2%) met the nirsevimab eligibility criteria, 76 (13.2%) had other identified RSV risk conditions, 96 (16.7%) had other preexisting conditions, and 355 (61.8%) had no preexisting conditions. A higher proportion of children who met nirsevimab eligibility criteria required invasive mechanical ventilation vs children with other identified RSV risk conditions, those with other preexisting health conditions, or those with no preexisting health conditions (40.4% [19 of 47] vs 17.1% [13 of 76], 10.4% [10 of 96], 5.9% [21 of 355]; P for trend <.001). Conclusions and Relevance Among children admitted to the PICU for severe RSV, 8.2% met the nirsevimab eligibility criteria and 13.2% had other identified RSV risk conditions. These findings might help inform future deliberations regarding second RSV season recommendations for nirsevimab eligibility in the US.

JAMA Network OpenVol. 9(11)
University of North Carolina at Chapel Hill (US), University of Iowa (US), Saint Barnabas Medical Center (US), Cincinnati Children's Hospital Medical Center (US), Boston Children's Hospital (US), Centers for Disease Control and Prevention (US), Lurie Children's Hospital (US), Children's Medical Center (US), Arkansas Children's Hospital (US), University of Minnesota (US), Primary Children's Hospital (US), Children's Mercy Hospital (US), Mayo Clinic (US), Children's Hospital of Philadelphia (US), Harvard University (US), Emory University (US), Medical University of South Carolina (US), Oregon Health & Science University (US), University of California, San Francisco (US), Pfizer (United States) (US), National Center for Immunization and Respiratory Diseases (US), University of Washington (US), University of Mississippi Medical Center (US), University of Alabama at Birmingham (US), University of California San Diego (US), Rady Children's Hospital-San Diego (US), Children's Hospital Colorado (US), Akron Children's Hospital (US), University of California San Francisco Medical Center (US), Children's Hospital of New Orleans (US), University of North Carolina Hospitals (US), University of Iowa Health Care (US), Children's Healthcare of Atlanta (US), Rainbow Babies & Children's Hospital (US), University of Minnesota Children's Hospital (US), Indiana University Indianapolis (US), UAB Medicine (US), Indiana University School of Medicine (US), Albany Medical College (US), Seattle Children's Research Institute (US), University of Colorado Anschutz Medical Campus (US), Indiana University – Purdue University Indianapolis (US), University of Cincinnati (US), Louisiana State University Health Sciences Center New Orleans (US), University of Missouri–Kansas City (US), Columbia University (US), The University of Texas Southwestern Medical Center (US), Vanderbilt University Medical Center (US), University of Cincinnati Medical Center (US)
Pfizer, Centers for Disease Control and Prevention
Good health and well-being
Respiratory viral infections research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon